Home›Oncology› Rezvilutamide plus ADT with efavirenz-based ART yields PSA decline in one HIV-positive mHSPC patient
Rezvilutamide plus ADT with efavirenz-based ART yields PSA decline in one HIV-positive mHSPC patientRezvilutamide Shows Promise for Prostate Cancer in HIV Patients
Frontiers in MedicinePublished September 13, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Interpret as hypothesis-generating only; no efficacy or safety conclusions possible from one case.
This case report describes one HIV-positive patient with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) treated with rezvilutamide plus androgen deprivation therapy (ADT) while continuing efavirenz-based antiretroviral therapy. The report focuses on the feasibility of treatment intensification in a patient with a comorbidity and a potential drug-drug interaction barrier.
The reported outcomes include a prostate-specific antigen (PSA) decline from 21,788.320 ng/mL to 4.315 ng/mL, clinical improvement, sustained HIV viral suppression, and a favorable short-term tolerability profile. No comparator, primary outcome definition, effect size, p-value, confidence interval, or follow-up duration was reported. Adverse events, serious adverse events, and discontinuations were not reported.
The authors acknowledge that this is a case report involving a single patient, which limits generalizability. The report does not establish efficacy or safety of rezvilutamide in this population and cannot distinguish treatment effect from other clinical factors. The rapid and profound PSA response and favorable short-term tolerability should not be overinterpreted.
Practice relevance is framed as a practical reference for implementing guideline-recommended treatment intensification principles in patients with comorbidities and drug-drug interaction barriers. Clinicians should interpret this as hypothesis-generating only and await data from larger studies before drawing conclusions about rezvilutamide use in HIV-positive patients with mHSPC.
How this fits prior evidence
This case report extends prior coverage of treatment intensification in mHSPC, where docetaxel and PARP inhibitor additions to ARPI and ADT improve progression-free survival, and darolutamide plus ADT and docetaxel reduces death risk 37%. It also relates to prior coverage of efavirenz 400 mg noninferiority to 600 mg for virological suppression. However, it provides only single-patient, uncontrolled observational data and does not confirm or refute those findings. It addresses a gap in describing treatment intensification in patients with HIV and drug-drug interaction barriers, but no comparative or long-term data are available.
A case report describes the treatment of one patient who had both an HIV infection and high-volume metastatic hormone-sensitive prostate cancer. The patient was treated with rezvilutamide combined with androgen deprivation therapy while continuing their standard antiretroviral therapy using efavirenz.
During the treatment, the patient's prostate-specific antigen (PSA) levels dropped significantly from 21,788.320 ng/mL to 4.315 ng/mL. Additionally, the patient maintained a steady and sustained suppression of the HIV virus. The treatment was reported to have a favorable short-term tolerability profile.
Because this report involves only one patient, the results cannot be used to confirm how the treatment will work for everyone. However, it provides a practical example of how doctors might manage complex cases where a patient has multiple conditions and potential drug interactions. Talk to your doctor to discuss how these findings might relate to specific medical needs.
What this means for you:
One case shows a significant PSA drop and stable HIV levels in a patient treated with rezvilutamide.
Common questions
What were the results for the patient with both HIV and prostate cancer?
The patient saw a significant decrease in prostate-specific antigen (PSA) levels, which dropped from 21,788.320 ng/mL to 4.315 ng/mL. The patient also maintained a sustained suppression of the HIV virus while receiving the combination of rezvilutamide and efavirenz-based therapy.
Was the treatment well-tolerated by the patient?
The report noted that the treatment had a favorable short-term tolerability profile. However, because this was a single case report, it does not provide enough data to determine long-term effects or how other patients might react to the medication.
How much evidence is there for this specific treatment combination?
This finding comes from a case report involving only one patient. While it provides a helpful example for managing complex cases with multiple conditions, the small sample size means the results are not yet enough to establish a standard of care for all patients.
This case report describes a patient with metastatic hormone-sensitive prostate cancer (mHSPC), high tumor burden, and concurrent HIV infection receiving continuous efavirenz (a potent CYP3A4 inducer), who was treated with an intensified regimen based on androgen deprivation therapy (ADT) combined with the novel androgen receptor inhibitor rezvilutamide. Under rigorous multidisciplinary monitoring, this regimen achieved a rapid and profound response, characterized by a decline in prostate-specific antigen (PSA) levels from 21,788.320 ng/mL to 4.315 ng/mL, significant clinical improvement, sustained HIV viral suppression, and a favorable short-term tolerability profile. This case directly addresses the controversies and challenges regarding the use of intensified therapy in patients with comorbidities in current clinical practice, suggesting that key drug-drug interaction barriers may be manageable through personalized strategies and proactive management. This case provides a practical reference for implementing guideline-recommended treatment intensification principles in similar complex clinical scenarios, offering clinically relevant insights.
